{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:35:39Z","timestamp":1790937339759,"version":"4.1.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Highly pathogenic avian H5N1 influenza viruses remain a pandemic threat. Antiviral drugs such as neuraminidase (NA) inhibitors will be crucial for disease control in the event of a pandemic. Should drug-resistant H5N1 viruses develop, all defense strategies will be compromised. To determine the likelihood and mechanisms of emergence of NA inhibitor-resistant H5N1 variants in humans, we serially passaged two H5N1 viruses, A\/Hong Kong\/213\/03 and A\/Turkey\/65-1242\/06, in normal human bronchial epithelial (NHBE) cells in the presence of oseltamivir, zanamivir, or peramivir. To monitor the emergence of changes associated with the adaptation of H5N1 viruses to humans, we passaged the strains in the absence of drugs. Under pressure of each NA inhibitor, A\/Turkey\/65-1242\/06 developed mutations in the hemagglutinin (HA) (H28R and P194L\/T215I) and NA (E119A) proteins that reduced virus binding to \u03b12,3-sialyl receptor and NA activity. Oseltamivir pressure selected a variant of A\/Hong Kong\/213\/03 virus with HA P194S mutation that decreased viral binding to \u03b12,6 receptor. Under peramivir pressure, A\/Hong Kong\/213\/03 virus developed a novel NA mutation, R156K, that reduced binding to all three drugs, caused about 90% loss of NA activity, and compromised replication in NHBE cells. Both strains were eliminated in NHBE cells when they were cultivated in the absence of drugs. Here, we show for the first time that decreased NA activity mediated through NA inhibitors is essential for the adaptation of pandemic H5N1 influenza virus to humans. This ability of decreased NA activity to promote H5N1 infection underlines the necessity to optimize management strategies for a plausible H5N1 pandemic.<\/jats:p>","DOI":"10.1128\/jvi.06774-11","type":"journal-article","created":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T21:41:17Z","timestamp":1330551677000},"page":"4724-4733","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["Decreased Neuraminidase Activity Is Important for the Adaptation of H5N1 Influenza Virus to Human Airway Epithelium"],"prefix":"10.1128","volume":"86","author":[{"given":"Natalia A.","family":"Ilyushina","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"},{"name":"D. I. Ivanovsky Institute of Virology RAMS, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai V.","family":"Bovin","sequence":"additional","affiliation":[{"name":"Shemyakin Institute of Bioorganic Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"},{"name":"Department of Pathology, University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother","author":"Alexander WJ","year":"2007","unstructured":"AlexanderWJ. 2007. Nasal and pharyngeal concentrations of peramivir following intramuscular and intravenous administration in health volunteers, poster A-1410. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.65.6.3022-3028.1991"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052211"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00737711"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/504723"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560031007"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054512"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.11.3771"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(92)90130-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61515-3"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2001.1007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.100133697"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007050170002"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.03.003"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.10.004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000043"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000933"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00047-11"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/4371108a"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1993.1459"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8418-8425.2003"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308001101"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2264-2272.2003"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00103-0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.070164"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq067"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048343"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.061506.213121"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0900648"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90588-3"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.11.8377-8384.1997"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-06"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1974-1976.2000"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(79)90362-2"},{"key":"e_1_3_3_36_2","first-page":"493","article-title":"A simple method for estimating fifty percent endpoints","volume":"27","author":"Reed LJ","year":"1938","unstructured":"ReedLJ MuenchH. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493\u2013497.","journal-title":"Am. J. Hyg."},{"key":"e_1_3_3_37_2","unstructured":"Roche Pharmaceuticals. 2006. Tamiflu (oseltamivir carboxylate) capsules and for oral suspension. Package insert. Hoffmann-La Roche Inc. Nutley NJ. http:\/\/www.tamiflu.com."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05114"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051938"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.352"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068205"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.002053"},{"key":"e_1_3_3_44_2","unstructured":"World Health Organization. 2011. Technical update: current evolution of avian influenza H5N1 viruses. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/influenza\/human_animal_interface\/tripartite_notes_H5N1.pdf."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01067-07"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01182-9"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.06774-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.06774-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:28:32Z","timestamp":1646476112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.06774-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1128\/JVI.06774-11"],"URL":"https:\/\/doi.org\/10.1128\/jvi.06774-11","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"2011-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}